Molecular Partners Equity 2024

Molecular Partners Aktienanalyse

What does Molecular Partners do?

Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Molecular Partners's Equity

Molecular Partners's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Molecular Partners's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Molecular Partners's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Molecular Partners's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Molecular Partners’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Molecular Partners stock

What is the equity of Molecular Partners this year?

Molecular Partners has equity of 176.43 M CHF this year.

What was the equity of Molecular Partners compared to the previous year?

The equity of Molecular Partners has increased/decreased by -24.98% decreased compared to the previous year.

What impact does a high equity have on investors of Molecular Partners?

A high equity is advantageous for investors of Molecular Partners as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Molecular Partners?

A low equity can be a risk for investors of Molecular Partners, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Molecular Partners affect the company?

An increase in equity of Molecular Partners can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Molecular Partners affect the company?

A reduction in equity of Molecular Partners can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Molecular Partners?

Some factors that can affect the equity of Molecular Partners include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Molecular Partners so important for investors?

The equity of Molecular Partners is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Molecular Partners take to change the equity?

To change equity, Molecular Partners can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Molecular Partners pay?

Over the past 12 months, Molecular Partners paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Partners is expected to pay a dividend of 0 CHF.

What is the dividend yield of Molecular Partners?

The current dividend yield of Molecular Partners is .

When does Molecular Partners pay dividends?

Molecular Partners pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Molecular Partners?

Molecular Partners paid dividends every year for the past 0 years.

What is the dividend of Molecular Partners?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Molecular Partners located?

Molecular Partners is assigned to the 'Health' sector.

Wann musste ich die Aktien von Molecular Partners kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Molecular Partners from 9/29/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Molecular Partners pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Molecular Partners in the year 2023?

In the year 2023, Molecular Partners distributed 0 CHF as dividends.

In which currency does Molecular Partners pay out the dividend?

The dividends of Molecular Partners are distributed in CHF.